In 2024, the World Health Organization (WHO) reported over 13 million dengue cases globally—the highest ever recorded. This surge has continued into 2025, prompting an unprecedented global response.
To combat the escalating health crisis, more people than ever have been immunized with dengue vaccines. In May 2024, WHO prequalified QDENGA, making it eligible for procurement by UN agencies such as UNICEF and PAHO . The vaccine is recommended for children aged 6–16 in regions with high dengue transmission.
As of May 8, 2025, QDENGA has been authorized in approximately 40 countries, with approvals pending in the Philippines and India. However, it remains unavailable in the United States, including Puerto Rico, where dengue has become endemic .
Takeda's QDENGA has seen a substantial increase in demand, with Q4 FY2024 revenue reaching JPY 35.6 billion (approximately $247.7 million), marking a 259% increase compared to the previous year . The company aims to produce 100 million doses annually by 2030, supported by a strategic partnership with India's Biological E. Limited, which will manufacture up to 50 million doses per year .
This expanded access to QDENGA is a critical step in addressing the growing threat of dengue, especially in endemic regions like Pakistan, where the risk of outbreaks remains high.
